## **Core Concept**
The question assesses knowledge of first-line antihypertensive drugs, which are recommended as initial treatments for hypertension due to their efficacy and safety profile. These typically include **ACE inhibitors**, **ARBs (Angiotensin Receptor Blockers)**, **CCBs (Calcium Channel Blockers)**, and **Thiazide diuretics**. The classification of antihypertensive agents into frontline or first-line therapy depends on guidelines such as those from the American College of Cardiology (ACC) and American Heart Association (AHA).

## **Why the Correct Answer is Right**
The correct answer, **D.**, likely represents a drug class not considered a first-line treatment for hypertension. Without specific drug names provided, we infer based on common classifications: ACE inhibitors, ARBs, CCBs, and thiazide diuretics are generally recommended as initial therapy for most patients with hypertension. Other classes, such as **beta-blockers**, are considered for specific indications like heart failure, post-myocardial infarction, or certain types of arrhythmias.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is likely one of the frontline antihypertensives (e.g., lisinopril, an ACE inhibitor; amlodipine, a CCB; losartan, an ARB; hydrochlorothiazide, a thiazide diuretic), making it incorrect as an answer to which is *not* a frontline antihypertensive.
- **Option B:** Similarly, this option would represent another first-line treatment, making it incorrect for the same reason.
- **Option C:** This would also be a frontline antihypertensive, making it incorrect.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that while **beta-blockers** are crucial in certain clinical scenarios (e.g., post-myocardial infarction, heart failure with reduced ejection fraction), they are not typically considered first-line for uncomplicated hypertension, except in specific cases. Guidelines often recommend them as add-on therapy or in patients with certain comorbidities.

## **Correct Answer:** D.